Kymera Therapeutics (KYMR) FCF Margin (2019 - 2026)
Kymera Therapeutics (KYMR) reported FCF Margin of 259.78% for Q1 2026, up 10048.0% year-over-year from N/an in Q1 2025, and up 88.85% quarter-over-quarter from 2329.37% in Q4 2025.
Kymera Therapeutics (KYMR) FCF Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of FCF Margin data on file, last reported at 259.78% in Q1 2026.
- FCF Margin for Q1 2026 came in at 259.78%, up 10048.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 474.01% (down 6650.0% YoY), and the FY2025 annual result was 597.64%, down 15717.0% from the prior year.
- FCF Margin rose to 259.78% in Q1 2026 per KYMR's latest filing, from 2329.37% in the prior quarter.
- Over five years, FCF Margin peaked at 7.48% in Q4 2023 and troughed at 2329.37% in Q4 2025.
- A 5-year average of 606.65% and a median of 423.79% in 2022 frame the typical range for FCF Margin.
- On a YoY basis, FCF Margin climbed as much as 34919 bps in 2025 and fell as far as 148112 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 247.28% in 2022, then jumped by 97 bps to 7.48% in 2023, then sank by 11246 bps to 848.26% in 2024, then sank by 175 bps to 2329.37% in 2025, then surged by 89 bps to 259.78% in 2026.
- Business Quant data shows KYMR's FCF Margin at 259.78% in Q1 2026, 2329.37% in Q4 2025, and 987.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -259.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -259.78% |
| Dec 31, 2025 | -2,329.37% |
| Sep 30, 2025 | -987.37% |
| Jun 30, 2025 | -527.88% |
| Mar 31, 2025 | -360.26% |
| Dec 31, 2024 | -848.26% |
| Sep 30, 2024 | -1,336.57% |
| Jun 30, 2024 | -185.67% |
| Mar 31, 2024 | -456.82% |
| Dec 31, 2023 | -7.48% |
| Sep 30, 2023 | -840.21% |
| Jun 30, 2023 | -278.71% |
| Mar 31, 2023 | -506.83% |
| Dec 31, 2022 | -247.28% |
| Sep 30, 2022 | -371.85% |
| Jun 30, 2022 | -344.97% |
| Mar 31, 2022 | -423.79% |
| Dec 31, 2021 | -254.36% |
| Sep 30, 2021 | -184.73% |
| Jun 30, 2021 | -168.14% |